ABBVIE

The U.S. FDA approved Bristol Myers Squibb's schizophrenia drug, Cobenfy (KarXT), which reduces symptoms without common side effects, acquired through the $14 billion takeover of Karuna Therapeutics. Expected to generate $2.5 billion in U.S. sales by 2030, it targets cholinergic receptors, unlike traditional dopamine-targeting antipsychotics. Bristol plans to launch the drug in late October at $1,850 per month, with 80% of patients covered by Medicare and Medicaid.

AbbVie submits Biologics License Application to FDA for Teliso-V, an investigational treatment for previously treated non-small cell lung cancer with c-Met overexpression.

AbbVie submitted a Biologics License Application to the FDA for accelerated approval of Teliso-V, a first-in-class antibody-drug conjugate targeting c-Met overexpressing nonsquamous NSCLC. Supported by Phase 2 LUMINOSITY trial data, Teliso-V aims to address unmet needs in NSCLC treatment, potentially becoming the first approved therapy for this specific patient population.

AbbVie submitted a Biologics License Application for Teliso-V, a first-in-class therapy targeting c-Met overexpressing NSCLC, based on Phase 2 LUMINOSITY trial data. If approved, it would address unmet needs in NSCLC treatment, offering hope for patients with poor prognosis.

AbbVie submitted a Biologics License Application for Teliso-V, a first-in-class ADC targeting c-Met overexpressing NSCLC, based on Phase 2 LUMINOSITY trial data. If approved, Teliso-V would address unmet needs in NSCLC treatment, offering a new option for patients with poor prognosis.

AbbVie submits Biologics License Application to FDA for Teliso-V, an ADC targeting c-Met overexpression in previously treated nonsquamous NSCLC, supported by Phase 2 LUMINOSITY trial data.

AbbVie's phase 3 TEMPO-1 trial showed tavapadon, a monotherapy for Parkinson disease, significantly improved MDS-UPDRS scores at week 26. The study involved 529 PD patients aged 40-80, with both 5 mg and 15 mg doses outperforming placebo. Secondary endpoints and safety profile were consistent with prior trials, supporting tavapadon's potential in PD treatment.

AbbVie's phase three TEMPO-1 trial showed significant improvements in early-stage Parkinson’s disease with tavapadon, a D1/D5 dopamine receptor partial agonist, compared to placebo. Both 5 mg and 15 mg doses led to reduced MDS-UPDRS scores, indicating better motor function. Side effects were mild to moderate, consistent with previous trials. The TEMPO program includes additional trials to assess tavapadon's efficacy and safety.

AbbVie's Phase 3 TEMPO-1 trial for tavapadon met primary and secondary endpoints, showing significant improvement in MDS-UPDRS Parts II and III scores at week 26. Results from TEMPO-2 trial expected by end of 2024.

Tavapadon, an AbbVie drug for early Parkinson’s disease, met phase 3 TEMPO-1 trial goals, improving motor skills in 529 participants. The trial showed significant improvements with 5 mg and 15 mg doses compared to placebo, with mild to moderate adverse events. Tavapadon also improved symptom control as an add-on to levodopa in another trial, with results from a flexible-dose monotherapy trial expected by year-end.